You are here

Amarin

Amarin's CEO resigns, leaving former interim chief to take over struggling drugmaker

Fierce Pharma

Tue, 06/4/24 - 11:50 am

Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt

Fierce Pharma

Wed, 07/19/23 - 11:48 am

Amarin’s feud with Sarissa Capital leads to CEO Karum Mikhail’s abrupt departure

Medical Devices and Diagnostics Industry

Sun, 04/2/23 - 04:24 pm

Alex Denner's firm takes over Amarin, ousts non-Sarissa board members

Endpoints

Tue, 03/7/23 - 11:22 am

Sarissa Capital

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Yahoo/Benzinga

Tue, 03/7/23 - 10:16 am

acute coronary syndrome

clinical trials

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

Fierce Pharma

Fri, 02/24/23 - 08:55 am

Struggling Amarin jousts with activist investor Sarissa as board vote nears

Fierce Pharma

Tue, 02/14/23 - 10:44 am

Why Amarin Stock Tumbled This Week

Motley Fool

Fri, 01/20/23 - 10:20 am

Why Amarin Stock Was a Winner Today

Motley Fool

Tue, 11/15/22 - 06:38 pm

Amarin stands behind Vascepa after new analysis raises questions about its efficacy

Fierce Pharma

Tue, 07/5/22 - 12:04 am

Amarin turns to job cuts as generics challenge its heart pill

BioPharma Dive

Tue, 06/7/22 - 10:18 am

Amarin CFO resigns amid cost-cutting measures, staff reduction of 40%

Endpoints

Mon, 06/6/22 - 11:38 pm

Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe

Fierce Pharma

Thu, 05/5/22 - 10:21 am

With sales sagging, Amarin sees progress on new Vascepa digital effort in the US

Fierce Pharma

Wed, 03/2/22 - 09:55 am

digital marketing

End-of-Year Restructuring Means Layoffs for These Companies

BioSpace

Tue, 11/16/21 - 11:57 am

Rigel Pharmaceuticals

Esperion Therapeutics

Acorda Therapeutics

Ziopharm Oncology

Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy

Fierce Pharma

Thu, 09/23/21 - 10:29 pm

ESC: Amarin touts Vascepa's ability to reduce repeat heart problems as it fights generic with 'skinny label' claim

Fierce Pharma

Mon, 08/23/21 - 11:32 pm

Amarin's Vascepa patent defense ends in a loss at the Supreme Court

Fierce Pharma

Mon, 06/21/21 - 10:09 pm

Amarin CEO Thero to Retire as Company Pivots Focus to Global Markets

BioSpace

Tue, 04/13/21 - 10:09 pm

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

Fierce Pharma

Tue, 04/6/21 - 11:02 pm

Pages